keyword
MENU ▼
Read by QxMD icon Read
search

Androgen deprivation therapy

keyword
https://www.readbyqxmd.com/read/28811384/loss-of-spdef-and-gain-of-tgfbi-activity-after-androgen-deprivation-therapy-promote-emt-and-bone-metastasis-of-prostate-cancer
#1
Wei-Yu Chen, Yuan-Chin Tsai, Hsiu-Lien Yeh, Florent Suau, Kuo-Ching Jiang, Ai-Ning Shao, Jiaoti Huang, Yen-Nien Liu
Androgen deprivation therapy (ADT) targeting the androgen receptor (AR) is a standard therapeutic regimen for treating prostate cancer. However, most tumors progress to metastatic castration-resistant prostate cancer after ADT. We identified the type 1, 2, and 4 collagen-binding protein transforming growth factor-β (TGFβ)-induced protein (TGFBI) as an important factor in the epithelial-to-mesenchymal transition (EMT) and malignant progression of prostate cancer. In prostate cancer cell lines, AR signaling stimulated the activity of the transcription factor SPDEF, which repressed the expression of TGFBI ADT, AR antagonism, or overexpression of TGFBI inhibited the activity of SPDEF and enhanced the proliferation rates of prostate cancer cells...
August 15, 2017: Science Signaling
https://www.readbyqxmd.com/read/28811363/targeting-ar-variant-coactivator-interactions-to-exploit-prostate-cancer-vulnerabilities
#2
Fiorella Magani, Stephanie O Peacock, Meghan A Rice, Maria J Martinez, Ann M Greene, Pablo S Magani, Rolando Lyles, Jonathan R Weitz, Kerry L Burnstein
Castration-resistant prostate cancer (CRPC) progresses rapidly and is incurable. Constitutively active androgen receptor splice variants (AR-Vs) represent a well-established mechanism of therapeutic resistance and disease progression. These variants lack the AR ligand-binding domain and, as such, are not inhibited by androgen deprivation therapy (ADT), which is the standard systemic approach for advanced PC. Signaling by AR-Vs, including the clinically relevant AR-V7, is augmented by Vav3, an established AR coactivator in CRPC...
August 15, 2017: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/28805047/outcomes-of-post-prostatectomy-radiotherapy-at-a-regional-cancer-centre
#3
Luke Nicholls, Amber Winter, Ashley Harwood, Ashley Plank, Preeti Bagga, Winnie Wong, Eric Khoo
INTRODUCTION: To investigate the efficacy and toxicity of radiation therapy (RT) after radical prostatectomy (RP) for prostate cancer at Radiation Oncology Centres, Toowoomba. METHODS: The electronic medical records of 130 consecutive patients with histologically proven prostate adenocarcinoma who underwent post-prostatectomy RT between January 2008 and December 2014 were analysed. Primary endpoint was Biochemical Recurrence (BCR) after RT. BCR was defined by PSA > 0...
August 14, 2017: Journal of Medical Radiation Sciences
https://www.readbyqxmd.com/read/28803700/association-of-androgen-deprivation-therapy-and-depression-in-the-treatment-of-prostate-cancer-a-systematic-review-and-meta-analysis
#4
Kevin T Nead, Sumi Sinha, David D Yang, Paul L Nguyen
BACKGROUND: There is increasing evidence that androgen deprivation therapy (ADT) may be associated with depression. Existing studies have shown conflicting results. METHODS: PubMed, Web of Science, Embase, and PsycINFO were queried on April 5, 2017. Eligible studies were in English and reported depression among individuals with prostate cancer exposed to a course of ADT vs. a lesser-exposed group (e.g., any-ADT vs. no ADT and continuous ADT vs. intermittent ADT)...
August 10, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28801240/exploring-all-avenues-for-radiotherapy-in-oligorecurrent-prostate-cancer-disease-limited-to-lymph-nodes-a-systematic-review-of-the-role-of-stereotactic-body-radiotherapy
#5
REVIEW
Elisabetta Ponti, Andrea Lancia, Piet Ost, Fabio Trippa, Luca Triggiani, Beatrice Detti, Gianluca Ingrosso
CONTEXT: Stereotactic body radiotherapy (SBRT) is emerging as a treatment option in patients affected by oligorecurrent prostate cancer disease limited to lymph nodes, a subgroup of patients who would otherwise be treated only with androgen deprivation therapy (ADT). OBJECTIVE: To perform a systematic review of SBRT for oligorecurrent prostate cancer limited to lymph nodes. EVIDENCE ACQUISITION: We performed a systematic review of PubMed/Medline in October 2016 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA)...
August 8, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28800492/adding-abiraterone-to-androgen-deprivation-therapy-in-men-with-metastatic-hormone-sensitive-prostate-cancer-a%C3%A2-systematic-review-and-meta-analysis
#6
Larysa H M Rydzewska, Sarah Burdett, Claire L Vale, Noel W Clarke, Karim Fizazi, Thian Kheoh, Malcolm D Mason, Branko Miladinovic, Nicholas D James, Mahesh K B Parmar, Melissa R Spears, Christopher J Sweeney, Matthew R Sydes, NamPhuong Tran, Jayne F Tierney
BACKGROUND: There is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive prostate cancer (mHSPC). This systematic review aims to assess the effects of adding abiraterone acetate plus prednisone/prednisolone (AAP) to ADT. METHODS: Using our framework for adaptive meta-analysis (FAME), we started the review process before trials had been reported and worked collaboratively with trial investigators to anticipate when eligible trial results would emerge...
August 8, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28797587/subcutaneous-adipose-tissue-characteristics-and-the-risk-of-biochemical-recurrence-in-men-with-high-risk-prostate-cancer
#7
Andrew M McDonald, John B Fiveash, Robert S Kirkland, Rex A Cardan, Rojymon Jacob, Robert Y Kim, Michael C Dobelbower, Eddy S Yang
PURPOSE/OBJECTIVE(S): To assess subcutaneous adipose tissue characteristics by computed tomography (CT) as potential imaging biomarkers predictive of biochemical recurrence in men with high-risk prostate cancer receiving radiotherapy (RT). MATERIALS AND METHODS: This retrospective study included men with high-risk prostate cancer (PSA>20ng/ml, Gleason score ≥8, or clinical extraprostatic extension) treated between 2001 and 2012. All patients received definitive, dose-escalated external beam RT along with a course of neoadjuvant, concurrent, and adjuvant androgen deprivation therapy (ADT)...
August 7, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28795303/the-feasibility-of-prostate-specific-membrane-antigen-positron-emission-tomography-psma-pet-ct-guided-radiotherapy-in-oligometastatic-prostate-cancer-patients
#8
O C Guler, B Engels, C Onal, H Everaert, R Van den Begin, T Gevaert, M de Ridder
BACKGROUND: To investigate the efficacy and toxicity of 68Ga-PSMA-HBED-CC ((68)Ga-PSMA) PET-CT-guided RT in the treatment of oligometastatic prostate cancer retrospectively. METHODS: A total of 23 prostate cancer patients with biochemical relapse, of which 13 were castration sensitive (CS) and 10 castration resistant (CR), were treated with intensity-modulated and image-guided RT (IMRT-IGRT) on ≤3 metastases detected by (68)Ga PSMA PET-CT. Androgen deprivation therapy was continued in CR patients...
August 9, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28791252/prostate-specific-antigen-5-years-following-stereotactic-body-radiation-therapy-for-low-and-intermediate-risk-prostate-cancer-an-ablative-procedure
#9
Shaan Kataria, Harsha Koneru, Shan Guleria, Malika Danner, Marilyn Ayoob, Thomas Yung, Siyuan Lei, Brian T Collins, Simeng Suy, John H Lynch, Thomas Kole, Sean P Collins
BACKGROUND: Our previous work on early PSA kinetics following prostate stereotactic body radiation therapy (SBRT) demonstrated that an initial rapid and then slow PSA decline may result in very low PSA nadirs. This retrospective study sought to evaluate the PSA nadir 5 years following SBRT for low- and intermediate-risk prostate cancer (PCa). METHODS: 65 low- and 80 intermediate-risk PCa patients were treated definitively with SBRT to 35-37.5 Gy in 5 fractions at Georgetown University Hospital between January 2008 and October 2011...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28783103/significance-of-micrornas-in-androgen-signaling-and-prostate-cancer-progression
#10
REVIEW
Ken-Ichi Takayama, Aya Misawa, Satoshi Inoue
The androgen receptor (AR) plays important roles in prostate cancer development and prostate tumor growth. After binding to androgens, AR functions as a nuclear receptor and translocates to the nucleus to bind to specific AR-binding sites (ARBSs). AR regulates epigenetic factor recruitments to activate its downstream signaling. Although androgen deprivation therapy (ADT) is initially useful for prostate cancer patients, most patients eventually show resistance with hormone-refractory prostate cancers (HRPCs) or castration-resistant prostate cancers (CRPCs)...
August 7, 2017: Cancers
https://www.readbyqxmd.com/read/28780479/q-twist-analysis-of-patients-with-metastatic-castrate-naive-prostate-cancer-treated-by-androgen-deprivation-therapy-with-or-without-docetaxel-in-the-randomised-phase-iii-getug-afu-15-trial
#11
P Marino, P Sfumato, F Joly, K Fizazi, S Oudard, S Culine, M Habibian, J-M Boher, G Gravis
BACKGROUND: Early chemotherapy has recently become a new standard of care for patients with metastatic castrate-naive prostate cancer (mCNPC). The survival benefit is evident in patients with high-volume disease, but less clear in those with low-volume disease. Here, we assessed the trade-offs between toxicity and survival using a Quality-adjusted Time Without Symptoms of disease and Toxicity of treatment (Q-TWiST) analysis. PATIENTS AND METHODS: This analysis was performed from the data of the Genito-Urinary Oncology Group (GETUG)-AFU 15 phase III trial evaluating the benefits of docetaxel (D) combined with androgen deprivation therapy (ADT) versus ADT alone in 385 mCNPC patients...
August 3, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28768300/androgen-deprivation-therapy-and-the-risk-of-anemia-in-men-with-prostate-cancer
#12
Blánaid M Hicks, Adi J Klil-Drori, Hui Yin, Lysanne Campeau, Laurent Azoulay
BACKGROUND: The use of androgen deprivation therapy in prostate cancer may be associated with an increased risk of anemia, but the evidence remains limited. This study aimed to determine if androgen deprivation is associated with increased risk of anemia in patients newly diagnosed with prostate cancer. METHODS: This was a population-based cohort study using the United Kingdom Clinical Practice Research Datalink linked to the Hospital Episode Statistics repository...
September 2017: Epidemiology
https://www.readbyqxmd.com/read/28764689/heterogeneity-in-high-risk-prostate-cancer-treated-with-high-dose-radiation-therapy-and-androgen-deprivation-therapy
#13
Daniel N Cagney, Mary Dunne, Carmel O'Shea, Marie Finn, Emma Noone, Martina Sheehan, Lesley McDonagh, Lydia O'Sullivan, Pierre Thirion, John Armstrong
BACKGROUND: Our aim was to assess the heterogeneity of high-risk (HR) prostate cancer managed with high-dose external beam radiotherapy (EBRT) with androgen deprivation therapy (ADT). METHODS: We identified 547 patients who were treated with modern EBRT from 1997 to 2013, of whom 98% received ADT. We analyzed biochemical relapse-free survival (bRFS) and distant metastases-free survival (DMFS). RESULTS: Median EBRT dose was 74 Gy, and median ADT duration was 8 months...
August 1, 2017: BMC Urology
https://www.readbyqxmd.com/read/28762529/the-impact-of-statin-use-on-the-efficacy-of-abiraterone-acetate-in-patients-with-castration-resistant-prostate-cancer
#14
Lauren C Harshman, Lillian Werner, Abhishek Tripathi, Xiaodong Wang, Benjamin L Maughan, Emmanuel S Antonarakis, Mari Nakabayashi, Rana McKay, Mark Pomerantz, Lorelei A Mucci, Mary-Ellen Taplin, Christopher J Sweeney, Gwo-Shu Mary Lee, Philip W Kantoff
BACKGROUND: Statins compete with DHEAS for influx through the SLCO2B1 transporter, which may prolong time to progression (TTP) on androgen deprivation therapy. Abiraterone acetate (AA) may also undergo SLCO-mediated transport. Based on preclinical findings showing antagonism, we hypothesized that statins may compete with AA for influx via SLCO2B1 and could negatively impact drug efficacy. METHODS: We queried two institutional clinical databases (Dana-Farber Cancer Institute [DFCI], Johns Hopkins University [JHU]) for CRPC patients treated with AA...
August 1, 2017: Prostate
https://www.readbyqxmd.com/read/28761362/targeted-tpx2-increases-chromosome-missegregation-and-suppresses-tumor-cell-growth-in-human-prostate-cancer
#15
Hung-Wei Pan, Hsing-Hao Su, Chao-Wen Hsu, Guan-Jin Huang, Tony Tong-Lin Wu
Prostate cancer is a complex disease that can be relatively harmless or extremely aggressive. Although androgen-deprivation therapy is a commonly used treatment for men with prostate cancer, the adverse effects can be detrimental to patient health and quality of life. Therefore, identifying new target genes for tumor growth will enable the development of novel therapeutic intervention. TPX2 plays a critical role in chromosome segregation machinery during mitosis. Low rates of chromosome missegregation can promote tumor development, whereas higher levels might promote cell death and suppress tumorigenesis...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28760556/bone-scan-index-is-an-independent-predictor-for-time-to-castration-resistant-prostate-cancer-in-newly-diagnosed-prostate-cancer-a-prospective-study
#16
Helle D Zacho, Michael Gade, Jesper C Mortensen, Henrik Bertelsen, Ren K Boldsen, Tamás Barsi, Lars J Petersen
OBJECTIVE: To prospectively determine the prognostic value of the bone scan index (BSI) for time to development of castration-resistant prostate cancer (CRPC) in consecutive, hormone-naïve patients with newly diagnosed prostate cancer. PATIENTS AND METHODS: Eligible patients participated in a prospective, observational, multi-center study of the value of bone scintigraphy (BS) at staging. BSI was determined using the EXINIBone(BSI)-software in 208 consecutive patients undergoing androgen deprivation therapy...
July 28, 2017: Urology
https://www.readbyqxmd.com/read/28760403/health-related-quality-of-life-for-immediate-versus-delayed-androgen-deprivation-therapy-in-patients-with-asymptomatic-non-curable-prostate-cancer-trog-03-06-and-vcog-pr-01-03-toad-a-randomised-multicentre-non-blinded-phase-3-trial
#17
Gillian M Duchesne, Henry H Woo, Madeleine King, Steven J Bowe, Martin R Stockler, Alice Ames, Catherine D'Este, Mark Frydenberg, Andrew Loblaw, Shawn Malone, Jeremy Millar, Keen Hun Tai, Sandra Turner
BACKGROUND: Androgen-deprivation therapy in patients with prostate cancer who have relapsed with rising prostate-specific antigen concentration only (PSA-only relapse), or with non-curable but asymptomatic disease at diagnosis, could adversely affect quality of life at a time when the disease itself does not. We aimed to compare the effect of immediate versus delayed androgen-deprivation therapy on health-related quality of life over 5 years in men enrolled in the TOAD (Timing of Androgen Deprivation) trial...
July 28, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28758177/the-5-year-outcomes-of-moderately-hypofractionated-radiotherapy-66%C3%A2-gy-in-22-fractions-3-fractions-per-week-for-localized-prostate-cancer-a-retrospective-study
#18
Yaichiro Hashimoto, Atsushi Motegi, Tetsuo Akimoto, Norio Mitsuhashi, Junpei Iizuka, Kazunari Tanabe, Yuka Ishii, Sawa Kono, Sachiko Izumi, Kumiko Karasawa
BACKGROUND: Hypofractionated radiotherapy using fewer and larger fractional doses may be more beneficial than conventional external-beam radiotherapy for localized prostate cancer. We evaluated the 5-year outcomes of moderately hypofractionated radiotherapy for localized prostate cancer. METHODS: We retrospectively evaluated 195 patients with localized prostate cancer (T1-3N0M0) who underwent intensity-modulated radiotherapy (IMRT) (66 Gy delivered in fractions of 3 Gy every other weekday) between May 2005 and December 2011...
July 31, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28756619/prostate-carcinoma-with-amphicrine-features-further-refining-the-spectrum-of-neuroendocrine-differentiation-in-tumours-of-primary-prostatic-origin
#19
Susan Prendeville, Issam Al-Bozom, Eva Compérat, Joan Sweet, Andrew J Evans, Mohamed Ben-Gashir, Ozgur Mete, Theodorus H van der Kwast, Michelle R Downes
OBJECTIVE: The current WHO classification categorises high grade neuroendocrine (NE) carcinomas of the prostate into small cell and large cell types. A distinct form of carcinoma demonstrating synchronous dual exocrine and NE differentiation, termed amphicrine carcinoma, has been described at various other sites, primarily within the gastrointestinal tract. In this study, we describe the clinicopathologic features of a series of metastatic prostatic carcinomas with amphicrine features...
July 30, 2017: Histopathology
https://www.readbyqxmd.com/read/28756295/actin-alpha-cardiac-muscle-1-gene-expression-is-upregulated-in-the-skeletal-muscle-of-men-undergoing-androgen-deprivation-therapy-for-prostate-cancer
#20
Ada S Cheung, Casey de Rooy, Itamar Levinger, Kesha Rana, Michele V Clarke, Jackie M How, Andrew Garnham, Catriona McLean, Jeffrey D Zajac, Rachel A Davey, Mathis Grossmann
Androgen deprivation therapy (ADT) decreases muscle mass and function but no human studies have investigated the underlying genetic or cellular effects. We tested the hypothesis that ADT will lead to changes in skeletal muscle gene expression, which may explain the adverse muscle phenotype seen clinically. We conducted a prospective cohort study of 9 men with localised prostate cancer who underwent a vastus lateralis biopsy before and after 4 weeks of ADT. Next-generation RNA sequencing was performed and genes differentially expressed following ADT underwent gene ontology mining using Ingenuity Pathway Analysis...
July 27, 2017: Journal of Steroid Biochemistry and Molecular Biology
keyword
keyword
58120
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"